AdvanCell, a Sydney, Australia-based radiopharmaceutical company with a platform technology for cancer treatment, closed an A$18m Series B financing.
The round was led by Morningside. Anthony Aiudi from Morningside has been appointed to the Board of AdvanCell.
The company intends to use the funds to accelerate growth and advance lead clinical program 212Pb-ADVC001, a treatment for metastatic prostate cancer, expand manufacturing platform footprint and progress internal and partnership programs.
Led by Andrew Adamovich, CEO and Founder, AdvanCell is a radiopharmaceutical company developing next-generation cancer treatment. Its Targeted Alpha Therapies are powered by a platform technology – an alpha isotope generator. The technology harnesses the natural decay and radiochemical properties of certain elements, in combination with specific targeting molecules, to selectively deliver cell-killing radiation to the tumour cell.
FinSMEs
24/08/2022